BLENREP is indicated for the treatment of adults with relapsed or refractory multiple myeloma who have received at least 4 prior therapies, including an anti-CD38 monoclonal antibody, a...

Jul 24, 2020 · Blenrep is indicated as monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.

Belantamab mafodotin, sold under the brand name Blenrep, is a monoclonal antibody conjugated with a cytotoxic agent for the treatment of relapsed and refractory multiple myeloma. [2] [5] [6] [3]

BLENREP is indicated for the treatment of adults with relapsed or refractory multiple myeloma who have received at least 4 prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent. This indication is approved under accelerated approval based on response rate [see Clinical Studies ...

BLENREP is indicated as monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent , and an anti-CD38 monoclonal antibody, . and who have demonstrated disease progression on the last therapy.

Treatment of adults with relapsed or refractory multiple myeloma who have received at least 4 prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an...

Find important information about the FDA's withdrawal of the U.S. license to manufacture BLENREP and the discontinuation of the REMS program.

BLENREP is used to treat adults who have cancer of the bone marrow called multiple myeloma. 2. What you need to know before you are given BLENREP. Do not receive BLENREP: - if you are allergic to belantamab mafodotin or any of the other ingredients of this medicine (listed in section 6). Check with your doctor . if you think this applies to you.

BLENREP is a cytotoxic anticancer medicinal product. Proper handling procedures should be followed. Use aseptic technique for the reconstitution and dilution of the dosing solution. The recommended dose of BLENREP is 2.5 mg/kg administered as …

Belantamab mafodotin is a humanized, afucosyated immuno-conjugate that is specific for B-cell Maturation Antigen (BCMA). The antibody is conjugated to a microtubule disrupting agent...